フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease PR...
SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND...
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to...
SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY PR...
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations PR...
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations PR...
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin PR...
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations PR...
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with...
Bausch Health Continuing Process Toward Separating Bausch + Lomb PR Newswire LAVAL, QC, Aug. 22, 2022 LAVAL...
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit PR...
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE) PR Newswire LAVAL, QC...
BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS PR Newswire LAVAL, QC, Aug. 9, 2022 Revenues of $1.967...
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation PR Newswire LAVAL, Quebec...
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9 PR Newswire LAVAL...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約